Kanaph Therapeutics is a biotech company that specializes in drug discovery and early-stage clinical trials. With a focus on oncology and autoimmune diseases, their goal is to develop next-generation therapeutics. In the field of oncology, Kanaph's pipeline consists of bi-specific antibodies and small molecules that have an enhanced immuno-stimulatory activity in the tumor micro-environment.

This leads to more efficient tumor eradication. For autoimmune diseases, they have bispecific Fc-fusions that target the alternative complement pathway while inhibiting angiogenesis and downstream complement activation. Headquartered in Seoul, Kanaph has assembled a team of experienced scientists with drug development expertise from Korea and the US.

By harnessing and integrating their knowledge, they strive to create innovative ideas and synergies that translate into the development of new therapies. As the leader in next-generation immuno-oncology and cancer therapies, Kanaph Therapeutics is at the forefront of advancing medical treatments